Pharmaceuticals
Johnson & Johnson succeeds in $30-bn tender offer for Actelion
31 Mar 2017
J&J had clinched the deal in December after raising its offer to $280 per share or $30 billion in cash, which included spinning off Actelion's research and development pipeline
China’s Creat Group offers to buy German blood plasma products maker Biotest for $1.3 bn
31 Mar 2017
FDA approves Dupixent to treat severe eczema
29 Mar 2017
